Hah (30/01/22 20:10:20)
I haven't updated myself on this topic for at least five years. So here's some help https://pubmed.ncbi.nlm.nih.gov/33806604/ Cefiderocol! Nice. Relebactam Vaborbactam "Meropenem-vaborbactam has recently demonstrated higher clinical cure rates versus best available therapy for the treatment of carbapenem-resistant Enterobacteriaceae (CRE), as well as for HABP and VABP. The safety and tolerability of imipenem-relebactam and meropenem-vaborbactam has been reported in various phase I pharmacokinetic studies and phase II and III clinical trials. Both combinations appear to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date. In conclusion, relebactam and vaborbactam serve to broaden the spectrum of imipenem and meropenem, respectively, against β-lactamase-producing Gram-negative bacilli. The exact roles for imipenem-relebactam and meropenem-vaborbactam will be defined by efficacy and safety data from further clinical trials." |
| back to main board | expand thread |
| This board has been visited 215922 times | Current time is 02/07/22 08:44:43 |